As Pharma giant Roche continues its dive into the digital health realm, it is releasing a new self-testing device for INR or blood coagulation levels, that can wirelessly connect to a smartphone app. The CoaguChek Vantus system, which is designed for Warfarin patients to monitor their coagulation levels, includes built in Bluetooth technology. Patients can now see their results on the app and...
The road to digital innovation in the pharma and healthcare space is going to take players across industries — from tech developers and engineers to researchers and clinicians, according to a panel of digital-focused VPs speaking at BIO 2018 in Boston.
Tech is opening up new avenues in research and development, as well as access to data from EHRs and other databases. In the past, the healthcare...
Like almost any field in the healthcare industry pharma wants to get in on the latest technology trends. Recently big pharma has been looking to artificial intelligence as another tool to help facilitate drug research and help the company progress.
At the World Medical Innovation Forum in Boston on April 24, a panel of pharma leaders discussed the future of AI in the industry.
“It's quite top...
Roche’s Accu-Chek Connect Diabetes Management App has hit yet another snag with the FDA. On February 15, the agency issued a Class 2 Device Recall for certain software versions of the app due to a bug that could lead users to self-administer inappropriate doses of insulin.
Roche issued an update correcting the bug back in June, and has posted notices on the Accu-Chek website urging users to...
Pharma giant Roche is set to acquire oncology EHR software firm Flatiron Health in the first half of 2018, the companies announced today in a statement. Roche will pay an additional $1.9 billion over the millions it had already invested into the company in 2016, and as a result of the deal will control all shares of Flatiron Health.
“This is an important step in our personalized healthcare...
Just two months after announcing the applications for its pre-certification program pilot, the FDA has announced the nine companies that will be participating. The list includes major tech companies Apple and Samsung; health tech companies Verily, Pear Therapeutics, Tidepool, and Phosphorus; pharmaceutical companies Roche and Johnson & Johnson; and Fitbit — an interesting inclusion insofaras...
As implantable CGM company Senseonics continues to wait for clearance from the FDA, the company isn't sitting on its hands. On a Q2 earnings call, CEO Tim Goodnow reported that the company continues to expand its operations in Europe, is close to a CE Mark for a longer-lasting second generation device, and is partnering with Roche and Type Zero on an artificial pancreas study with an eye on...
Senseonics and TypeZero's R&D partnership around the artificial pancreas is leveling up. The two organizations announced today that they would team up with pharmaceutical and medical device company Roche to launch three European clinical trials of their combined closed-loop system. The research is backed by the National Institutes of Health (NIH) through its International Diabetes Closed Loop...
With all the recent technological approaches to clinical trials as of late, it’s clear that the notoriously long, expensive and often inefficient traditional process could use an update. From AI-powered matching platforms to increasingly sophisticated software to streamline data collection during trials, the space is getting busier.
Palo Alto-based monARC Bionetworks is one of the latest to make...
The relationship between global pharmaceutical company Roche and digital diabetes management app maker mySugr has been growing for the past couple of years. First there was the investment, then there was the partnership, and now Roche is going all in and becoming the exclusive shareholder of mySugr.
Under the agreement, mySugr will continue to function as a separate legal entity, but will serve...
